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Abstract:  Compared to the substantial volume of research on the general health 
consequences associated with chronic smoking, little research has been specifically 
devoted to the investigation of its effects on human neurobiology and neurocognition.   
This review summarizes the peer-reviewed literature on the neurocognitive and 
neurobiological implications of chronic cigarette smoking in cohorts that were not seeking 
treatment for substance use or psychiatric disorders. Studies that specifically assessed the 
neurocognitive or neurobiological (with emphasis on computed tomography and magnetic  
resonance-based neuroimaging studies) consequences of chronic smoking are highlighted. 
Chronic cigarette smoking appears to be associated with deficiencies in executive 
functions, cognitive flexibility, general intellectual abilities, learning and/or memory 
processing speed, and working memory. Chronic smoking is related to global brain atrophy 
and to structural and biochemical abnormalities in anterior frontal regions, subcortical 
nuclei and commissural white matter. Chronic smoking may also be associated with an 
increased risk for various forms of neurodegenerative diseases. The existing literature is 
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limited by inconsistent accounting for potentially confounding biomedical and psychiatric 
conditions, focus on cross-sectional studies with middle aged and older adults and the 
absence of studies concurrently assessing neurocognitive, neurobiological and genetic 
factors in the same cohort. Consequently, the mechanisms promoting the neurocognitive 
and neurobiological abnormalities reported in chronic smokers are unclear. Longitudinal 
studies are needed to determine if the smoking-related neurobiological and neurocognitive 
abnormalities increase over time and/or show recovery with sustained smoking cessation. 
Keywords: chronic cigarette smoking; neurocognition; neurobiology; neuroimaging; genetics 
 
1. Introduction 
Approximately 2 billion people worldwide use tobacco products, mostly in the form of cigarettes, 
with tobacco smoking-related diseases resulting in 4 million deaths per year [1]. Among the 
approximately 64.5 million active smokers in the USA, smoking-related disease results in 
approximately 440,000 preventable annual deaths [2]. The enormous healthcare expenditures and 
mortality associated with chronic cigarette smoking results in an estimated $92 billion annual 
productivity loss in the US. Internationally, the greatest smoking related mortality is increasingly 
apparent among economically disadvantaged groups, which, in the US includes a disproportionate 
number of ethnic minorities and those with psychiatric and substance use disorders [3,4]. An extensive 
body of research thoroughly describes the deleterious effects of chronic cigarette smoking on human 
cardiac and pulmonary function, peripheral vascular systems as well as its carcinogenic   
properties [5-8]. Recent research indicates chronic cigarette smoking is associated with increased risk 
for numerous biomedical conditions that may directly or indirectly compromise brain neurobiology 
and neurocognition [9-12]. However, compared to the substantial volume of research on the 
cardiovascular, pulmonary and cancer-related health consequences associated with chronic smoking, 
surprisingly little research has been specifically devoted to the investigation of its effects on human 
neurocognition and brain neurobiology.  
This review summarizes the peer-reviewed literature on the neurocognitive and neurobiological 
repercussions of chronic cigarette smoking in cohorts and population-based samples that were not 
specifically seeking treatment for substance use or psychiatric disorders. Prospective or retrospective 
studies that expressly assessed the neurocognitive or neurobiological consequences of chronic smoking 
are targeted. Research employing proton magnetic resonance-based studies of brain morphology and 
metabolites that specifically evaluated the neurobiological consequences of chronic smoking are 
emphasized. In this review, non-smoking control groups are referred to as NSC and individuals 
comprising these groups generally were indicated to be never smokers or consumed less than 100 
cigarettes over lifetime. NSC were equivalent in age to smoking cohorts unless otherwise specified. 
The research reviewed was generally conducted with individuals in one of three age ranges: 18–30, 
40–59 and 60–90. Individuals 18–30 years of age are referred to as “young adults”, 40–59 as   
“middle-aged adults” and 60–90 years of age as “older adults”. In studies where the participants do not 
conform to the above defined age groups, specific age ranges are provided. For reviews on the effects Int. J. Environ. Res. Public Health 2010, 7          
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of chronic smoking on brain neurobiology and function in alcohol and substance use disorders   
see [13-15]. Please refer to [16-20] for thorough reviews on the acute effects of nicotine administration 
and nicotine withdrawal on brain neurobiology and neurocognition (although not the focus of this 
review, these topics are briefly addressed in Section 4). For inclusive reviews on functional MRI and 
nuclear imaging findings in chronic smokers see [21,22]. 
2. Neurocognitive Consequences of Chronic Cigarette Smoking (see Table 1). 
The vast majority of research investigating the neurocognitive consequences of chronic cigarette 
smoking is cross-sectional in design and focused primarily on middle-aged and older adults. In the sole 
study of adolescents, daily smokers (mean age = 17  1) showed deficits in accuracy of working 
memory relative to NSC, with individuals who began smoking at a younger age demonstrating greater 
impairment than those who began smoking at a later age [23]. In the few studies with young adults, 
smokers were inferior to NSC on measures of sustained attention and impulse control [24],   
auditory-verbal memory, oral arithmetic, and receptive and expressive vocabulary [25], information 
processing speed [26] and general intelligence [27]. On an experimental behavioral measure of   
risk-taking (Balloon Analogue Risk Task [28]), young adults smokers demonstrated higher levels of  
risk-taking [29]. In cross-sectional studies specifically comparing NSC to middle-aged and/or older 
adult smokers, poorer performance in smokers was reported for auditory-verbal learning and/or 
memory [30-34], working memory [26,35,36], executive functions [33,37,38], general intellectual 
abilities [39], visual search speed [40], processing speed and cognitive flexibility [30-32,38,41,42] and 
global cognitive function (e.g., brief mental status examinations such as the MMSE) [41]. In a   
middle-aged cohort of combined current and former smokers, any history of smoking was associated 
with increased risk for abnormal auditory-verbal memory [43]. Some studies observed the 
performance of former smokers fell between that of current smokers and NSC in young [25],   
middle-aged and older adults [31,35,39]. Other studies found no differences between former smokers 
and NSC [25,30]. The inconsistencies among these studies may be related to the substantial variety of 
measures used across studies to evaluate the domain of functioning in question as well as 
inconsistency in the magnitude of neurocognitive dysfunction in the smoking study cohort.  
In cross-sectional population-based studies with community-dwelling older adults, where smoking 
status (i.e., current smoker, past smoker, never smoker) was used as a prospective or retrospective 
predictor, current smoking [44-46] and any history of smoking [47] were associated with poorer 
performances on measures of global cognitive function. Any previous smoking history (with variable 
lengths of smoking cessation) was associated with poorer cognitive flexibility [45], and impaired 
general cognitive function [44] or, conversely, decreased risk of global cognitive impairment [46]. 
Chronic smoking in older adults has also been associated with a diminished ability to execute some 
activities of daily living [48] and compromised postural stability [49].  
Longitudinal research with non-demented, population-based samples found that current cigarette 
smokers demonstrated an abnormal rate of decline on indices of reasoning [43] and auditory-verbal 
memory [40] in middle aged adults, and abnormal decline on measures of global cognitive function 
[47,50-53] and auditory-verbal memory in older adults [54].  Int. J. Environ. Res. Public Health 2010, 7          
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Sex effects in neurocognition among smokers have also been addressed in some studies.   
Edelstein  et al. [34] found no differences between older adult male smokers and male NSC on 
measures of global cognitive functioning, set-shifting, semantic fluency and auditory-verbal and 
visuospatial learning and memory, while older adult female smokers demonstrated poorer global 
cognitive functioning and auditory-verbal memory than female NSC. Jacobsen and colleagues [23] 
reported that male adolescent smokers performed more poorly than did female smokers on measures of 
selective and divided attention. Similarly, Razani and colleagues [37] observed that sex was a 
significant predictor of non-verbal abstraction in currently smoking older adults, however, no 
interactions were reported among sex, smoking status or smoking severity. Other studies, however, 
have found no sex effects on neurocognition in middle aged and older adults [32,33,39]. 
The level and chronicity of smoking, as reflected in the number of cigarettes smoked per day, 
duration of smoking over lifetime, and/or dose-duration (i.e., pack-years) were inversely related to 
various domains of neurocognition in adults across a wide age range [25,30,32,45,52,55,56]. Several 
reports indicate chronic smoking is associated with increased risk for various forms of dementia, in 
particular Alzheimer’s Disease and vascular dementia [57-61]. This risk may be modulated through the 
apolipoprotein E ε4 (ApoE4) genotype, a known genetic risk for the development of Alzheimer’s 
Disease [52,54]. Interestingly, some studies have reported that risk for development of Alzheimer’s 
Disease was greater in smokers who were not ApoE4 carriers [52,54,58,59]. 
Several studies, smoking status (i.e., smoker or non-smoker) or measures of smoking consumption 
(e.g., pack years), showed weak or no relationships to specific neurocognitive functions (e.g., measures 
of learning and memory, mental arithmetic, verbal fluency, processing speed), global neurocognitive 
function (e.g., MMSE) and neurocognitive decline in young and middle aged adults [62,63] and in large 
community-based samples consisting of middle-aged and older adults [64-70].  
Table 1. Neurocognitive studies of chronic smoking in adults (sorted by age group, then 
year of publication). 
Authors 
[reference 
number] 
Smokers 
(n) 
NSC  
(n) 
Age group/ 
Mean age 
or (range) 
Neurocognitive measures  
or domains assessed 
 
Major findings (all reported 
findings are statistically significant 
unless otherwise indicated) 
Jacobsen et al. 
(2005) [23] 
41 current  32  Adolescents & 
Young adults/ 
16.8 ± 1.2 
Hopkins Verbal Learning 
Test-Revised n-back task 
(measure of working memory, 
Connors Continuous 
Performance Task, auditory 
and visual selective attention, 
verbal and visuospatial 
divided attention 
Smokers demonstrated poorer 
working memory than NSC. 
Earlier age of smoking onset was 
related to poorer working memory.
Male smokers were inferior to 
female smokers on measures of 
selective and divided attention. 
Spilich et al. 
(1992) [71] 
45 current  45  Young adults/ 
19.2 ± 1.2 
Visual search speed/accuracy, 
sustained visual attention, 
working, memory, 
information processing speed 
Smokers performed worse than 
NSC on all measures of sustained 
attention and information 
processing speed. 
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Table 1. Cont. 
Authors 
[reference 
number] 
Smokers 
(n) 
NSC 
(n) 
Age group/ 
Mean age 
or (range) 
Neurocognitive measures 
or domains assessed 
Major findings (findings are 
statistically significant unless 
otherwise indicated) 
Elwan et al. 
(1997) [70] 
60 current  69  Young adults 
through older 
adults/49.9 ± 
3.8 (20–76) 
Paced Auditory Serial 
Attention Test, Trail Making 
Test A and B 
No significant differences observed 
between smokers and NSC on any 
measure. 
Lejuez et al. 
(2002) [72] 
26 current  34  Young adults/ 
20.1 ± 2.8 
Balloon Analogue Risk Task 
(BART), Iowa Gambling  
Task (IGT)  
Smokers demonstrated increased risk-
taking levels on the BART compared to 
NSC. Smokers and NSC showed no 
differences on the IGT. 
Fried et al. 
(2006) [25] 
27 current 
11 former 
64 Young  adults/ 
(17–21) 
WAIS-III, Wechsler Memory 
Scale-III, Peabody Picture 
Vocabulary, Test of Variables 
of Attention 
Overall, current smokers performed 
worse than NSC on measures of 
receptive and expressive language, oral 
arithmetic and auditory-verbal memory. 
Yakir et al. 
(2007) [24] 
91 current 
40 former 
151 Young  adults 
(all female)/ 
23.9 ± 2.2 
CogScan (v4.0): a 
comprehensive battery 
assessing information 
processing speed, sustained 
attention, fine motor skills, 
auditory-verbal and 
visuospatial memory, 
reasoning and impulsivity. 
Current smokers showed poorer 
sustained attention, impulse control and 
planning/reasoning than NSC. Former 
smokers had poorer impulse control and 
planning/reasoning than NSC. Current 
and former smokers were not 
significantly different on any measure. 
Weiser et al. 
(2009) [27] 
5762 
current 
695 former 
13,764 Young adults 
(all males)/ 
(18–21) 
Measures of verbal 
comprehension, verbal and 
non-verbal abstraction, and 
mathematical knowledge, 
Individual measures combined 
to form composite score of 
general IQ.  
Current and former smokers performed 
worse than NSC, although the difference 
between former smokers and NSC was 
trivial with respect to effect size after 
adjustment for socioeconomic status. 
Current smokers who smoked more than 
11 cigarettes per day showed the poorest 
performance relative to NSC. 
Ernst et al. 
(2001) [35] 
14 current 
15 former 
9 Young  and 
Middle aged 
adults/ 
(21–45) 
Domains assessed were verbal 
reasoning and working 
memory. 
Current smokers and former smokers 
showed poorer working memory than 
NSC. Current smokers had poorer 
working memory than former smokers. 
Sakurai and 
Kanazawa 
(2002) [62] 
20 current  20  Young and 
Middle aged 
Adults/ 
(23–41) 
Measures of auditory-verbal 
learning and memory, mental 
arithmetic, and verbal fluency 
No differences between smokers and 
NSC on any task. 
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Table 1. Cont. 
Authors 
[reference 
number] 
Smokers  
(n) 
NSC 
(n) 
Age group/ 
Mean age 
or (range) 
Neurocognitive measures  
or domains assessed 
Major findings (findings are 
statistically significant unless 
otherwise indicated) 
Paul et al. 
(2006) [33] 
62 current  62  Young and 
middle aged 
adults/  
28.1 ± 7.2, 
55.2 ± 7.3 
Domains assessed included 
executive function, finger 
tapping speed, learning and 
memory, sustained attention, 
word fluency, working memory
Smokers performed more poorly 
than NSC on one measure of 
executive function. Middle aged 
smokers showed poorer  
auditory-verbal memory than aged 
NSC and young adult smokers. 
George et al. 
(2002) [36] 
29 current  16  Middle aged 
adults/  
41.5 ± 10.3 
Domains assessed were 
visuospatial working memory, 
cognitive flexibility 
Smokers exhibited worse 
visuospatial working memory. 
Schinka et al. 
(2002)  
[67] 
174 current 
80 former 
204 Middle  aged 
adults/ 
38.4 ± 2.3 
CVLT, WAIS-R Block Design, 
Rey-Osterreith Complex 
Figure, Wisconsin Card Sorting 
Test, Paced Auditory Serial 
Attention Test, Grooved 
Pegboard, semantic fluency, 
global cognitive function 
Higher pack years of smoking was 
related to lower global cognitive 
functioning. 
Kalmijn et al. 
(2002) [32] 
529 current 
715 former 
619 Middle  aged 
adults/  
56.4 ± 7.1 
Domains assessed were 
auditory-verbal and 
visuospatial learning and 
memory, cognitive flexibility, 
processing speed, global 
cognitive function 
Current smokers showed poorer 
cognitive flexibility and processing 
speed than NSC. No differences 
between former smokers and NSC 
on any measure. 
Sabia et al. 
(2008) [43] 
815 current 
2,030 former 
2,543 Middle  age 
adults/ 
56 ± 6 
Mill Hill Vocabulary Test, 
measures of verbal and 
semantic fluency, verbal and 
mathematical reasoning, 
auditory verbal learning 
In cross-sectional analyses, smoking 
history was associated with 
increased risk of poor memory. 
Over 4–7 years, current smokers and 
recent former smokers showed 
significantly greater declines in 
reasoning than never smokers. No 
significant declines in cognitive 
function were observed in former 
smokers. 
Cerhan et al. 
(1998) [56] 
13,913 total 
participants, 
numbers of 
current, former 
smokers and 
NSC not 
provided 
NA Middle  age 
and older 
adults/ 
(45–69) 
WAIS-R Digit Symbol Test, 
measures of auditory-verbal 
memory and verbal fluency 
Current smokers demonstrated 
poorer performance on Digit 
Symbol and auditory-verbal 
memory. For smokers, greater 
lifetime number of cigarettes was 
related to poorer Digit Symbol and 
auditory-verbal memory 
performance. 
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Table 1. Cont.  
Authors 
[Reference 
Numbrer] 
Smokers  
(n) 
NSC 
(n) 
Age group/ 
Mean age 
or (range) 
Neurocognitive 
measures or domains 
assessed 
Major findings (findings are 
statistically significant unless 
otherwise indicated) 
Hill et al. 
(2003) [30] 
164 current  438  Middle aged 
& older 
adults/NA 
WAIS-R Block Design 
and measures of  
auditory-verbal learning 
and memory, general 
knowledge, word 
comprehension 
Smokers, irrespective of age performed 
worse than NSC on Block Design and  
on measures of auditory-verbal memory.
Razani et al. 
(2004) [73] 
125 former or 
never smokers. 
Groups were  
retro-spectively 
divided into 
non/light, 
moderate heavy 
and heavy 
smokers based on 
pack years. Only 2 
of 127 subjects 
were active 
smokers. 
NA Middle  aged 
& older adults 
65.9 ± 8.3 
WAIS-R Digit Symbol 
and Digit Span, WMS-R 
Logical Memory and  
Visual Reproduction,  
Rey-Osterrieth Complex 
Figure—Immediate 
Recall, Stroop Word and 
color trials, WCST 
Heavy smokers performed worse than 
moderate smokers and non/light 
 smokers on the WCST.  
Hill (1989) 
[42] 
11 current 
12 former 
53 Older  adults/
71.6 ± 4.9 
WAIS-R Block Design, 
Digit Symbol, and Digit 
Span; WMS Logical 
Memory and Associative 
Memory, Bender Gestalt, 
Cross Off Task, word 
fluency and Digit Symbol.
At the baseline assessment current 
smokers performed worse than former 
smokers and NSC on the Cross Off task. 
At reassessment (15 months after 
baseline), current smokers performed 
worse than former and current smokers 
on the Cross Off Task and Digit Symbol.
Hebert et al. 
(1993) [69] 
current 
former 
 
 Older 
adults/(65 to 
≥ 80) 
Measures of  
auditory-verbal memory, 
working memory and 
orientation 
Current and former smokers showed no 
significant decline over a 3-year period 
on any measure relative to NSC after 
control for age, sex, education and 
income.  
Launer et al. 
(1996) [53] 
110 current 
288 former 
91 Older  adults/ 
75 ± 4.5 
MMSE  Smokers performed worse on the MMSE 
than NSC after correction for age, 
education and alcohol consumption.  
Over a 3-year period, current smokers 
with cardiovascular disease and/or 
diabetes showed the greatest decline in 
MMSE scores. 
Ford et al. 
(1996) [68] 
259 current and 
former smokers 
combined 
369 Older 
adults/>75 
Pfeiffer Short Portable 
Mental Status 
Questionnaire (PSPMSQ) 
Baseline and change over 4 years on the 
PSPMSQ was not associated with 
smoking status. 
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Table 1. Cont. 
Authors 
[reference 
number] 
Smokers 
(n) 
NSC 
(n) 
Age group/ 
Mean age 
or (range) 
Neurocognitive measures 
or domains assessed 
Major findings (all reported finding 
are statistically significant unless 
otherwise indicated) 
Galanis et al. 
(1997) [46] 
921 current 
1,334 former 
1,174 Older  adults/ 
77.4 ± 4.6 
Cognitive Abilities Screening 
Test (CASI): includes task of 
attention, concentration 
abstraction, judgment, verbal 
and verbal fluency. A 
composite CASI score was 
formed from the individual 
components. 
After adjustment for age, education and 
Japanese acculturation, current and 
former smokers had lower CASI  
score than never smokers. Higher risk  
of impaired performance on CASI  
scores was associated with current and  
former smoking. 
Edelstein  
et al. (1998) 
[34] 
114 current  407  Older adults/ 
72.0 ± 9.2 
MMSE, Trail Making Test 
Part–B, Buschke Selective 
Reminding Test, Modified 
Version of WMS Visual 
Reproduction, semantic 
fluency and auditory-verbal 
memory. 
No differences between male smokers 
and male NSC. Female smokers 
demonstrated poorer performance than 
female NSC on the MMSE. 
Cervilla  
et al. (2000) 
[51] 
80 current 
204 former 
134 Older  adults/ 
(65–95) 
Organic Brain Syndrome Scale 
(OBS) (measure of orientation 
to person time, place and 
context) 
After controlling for sex, age, alcohol 
consumption, education, depression and 
baseline cognitive function, current 
smokers had a 3.7 fold risk of impaired 
performance on the OBS after one year. 
Schinka  
et al. (2002) 
[64] 
334 
participants 
with various 
smoking and 
alcohol use 
histories. 
61 Older  adults/ 
(60–84) 
MMSE, Hopkins Verbal 
Learning Test, Stroop Color 
Word test, Trail Making Test  
Part–B 
No significant effects were found for 
alcohol or cigarette consumption on  
any measure. 
Chen et al. 
(2003) [66] 
195 current 
51 former 
68 Older  adults/ 
72 ± 6 
Cognitive Abilities Screening 
Instrument (measure of global 
cognitive function) 
No significant group differences on the 
Cognitive Abilities Screening 
Instrument. 
Deary et al. 
(2003) [39] 
126 current 
278 former 
 
387 Older  adults/ 
75.6 ± 5.4 
Moray House Test (MHT). 
Included measures of verbal, 
numerical, and verbal 
reasoning. Global MHT score 
formed from the individual 
components. 
After adjusting for MHT score at age  
11 years of age, education and sex, 
current smokers had lower MHT scores 
than NSC and former smokers. NSC  
and former smokers were not different. 
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Table 1. Cont. 
Authors 
[reference 
number] 
Smokers (n)  NSC (n)  Age group/ 
Mean age 
or (range) 
Neurocognitive 
measures or domains 
assessed 
Major findings (all reported finding 
are statistically significant unless 
otherwise indicated) 
Schinka  
et al. (2003) 
[65] 
30 current  86  Older adults/ 
(60–84) 
MMSE, Hopkins Verbal 
Learning Test, Stroop 
Color-Word Test 
Pack years significantly predicted 
MMSE and auditory-verbal memory 
scores, but only accounted for 1.8% of 
variance in auditory-verbal memory. 
Huadong  
et al. (2003) 
[44] 
720 current 
276 former 
1,976 Older 
adults/>60 
MMSE  Current smokers had 2.3 greater risk of 
impaired MMSE score (i.e., <17) 
relative to NSC after adjustment for 
age, sex, education, occupation and 
alcohol use. 
Ott et al. 
(2004) [50] 
2,037 current 
3,372 former 
3,800 Older 
adults/>65 
MMSE  Current smokers relative to never 
smokers showed a greater rate of 
decrease in MMSE scores over 
approximately 2 years controlled for 
age, sex, education, baseline MMSE, 
history of myocardial infarction, and 
cerebrovascular accident. Higher pack 
years was associated with higher rate 
of decline in MMSE. 
Reitz et al. 
(2005) [54] 
90 current 
135 former 
184 Older  adults/ 
75.6 ± 5.4 
MMSE, Boston Diagnostic 
Aphasia Evaluation: 
Boston Naming Test, 
Category Naming, Phrase 
Repetition, Complex 
Ideational Material,  
WAIS-R Similarities, 
Nonverbal Identities and 
Oddities from The DRS, 
Rosen Drawing Test, 
Buschke Selective 
Reminding Test, Benton 
Visual Retention Test. 
Over approximately five years, there 
was no association between current or 
former smoking status and change in 
cognition in those <75 years of age. 
For those >75 years of age, current 
smokers showed greater decline in 
memory than former smokers and 
NSC. The memory declines were 
greatest in current smokers who were 
not carriers of the ApoEε4 allele. 
Whalley  
et al. (2005) 
[41] 
90 current 
135 former 
184 Older 
adults/64 
Raven’s Standard 
Progressive Matrices, Rey 
Auditory Verbal Learning 
Test, WAIS-R Digit 
Symbol and Block Design, 
Uses of Common Objects 
Test and a composite 
measure of all tests. 
After adjusting for childhood IQ, age, 
education, occupation, lung function, 
any history of smoking was associated 
with lower scores on Digit Symbol. 
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Table 1. Cont. 
Authors 
[reference 
number] 
Smokers (n)  NSC 
(n) 
Age group/ 
Mean age 
or (range) 
Neurocognitive measures 
or domains assessed 
Major findings (findings are 
statistically significant unless 
otherwise indicated) 
Fischer et al. 
(2006) [47] 
262current 
75 former 
NA Older 
adults/75 
MMSE  Longer duration of smoking was 
associated with lower MMSE after 
adjusting for vascular risk factors and 
use of antihypertensive medication.
Stewart et al. 
(2006) [45] 
135current 
246 former 
217 Older  adults/
64.5 ± 6.5 
Raven’s Standard 
Progressive Matrices, Rey 
Auditory Verbal Learning 
Test, Trail Making Test, 
Digit Symbol Test, Mill Hill 
Vocabulary Scale (MHS), 
MMSE and a composite 
measure of all tests. 
In men, after adjusting for age, blood 
pressure and total cholesterol, higher 
pack years was associated lower scores 
on Auditory-verbal leaning, Digit 
Symbol Test, MHS in men. In women, 
higher pack years was associated with 
lower MMSE. In women, current 
smoking status was associated with 
poorer auditory-verbal learning. 
Starr et al. 
(2006) [31] 
289 total 
participants. 
Number of 
smokers, 
NSC, not 
provided 
NA Older 
adults/64 
and 66 
Raven’s Standard 
Progressive Matrices, Rey 
Auditory Verbal Learning 
Test, WAIS-R Digit Symbol 
and Block Design, Uses of 
Common Objects Test 
Current smokers performed worse 
NSC and former smokers on  
auditory-verbal learning and 
information processing speed after 
adjusting for childhood IQ. 
Note. DRS: Mattis Dementia Rating Scale; MMSE: Mini Mental Status Examination; NA: Not available; 
NSC: non-smoking (never-smoker) control; WAIS-III: Wechsler Adult Intelligence Scale-3rd Edition; 
WAIS-R: Wechsler Adult Intelligence-Revised; WMS-R: Wechsler Memory Scale-Revised. 
3. Neurobiological Consequences of Chronic Cigarette Smoking (See Table 2) 
The specific neurobiological factors underlying the reported smoking-related cognitive deficits are 
not established. However, there are a few of computed tomography (CT) and magnetic resonance 
(MR)-based studies that suggest the reported neurocognitive deficiencies in smokers may be, in part, 
mediated by abnormalities in brain morphology, perfusion and/or neurochemistry. The majority of 
these studies are cross-sectional in design. 
3.1. Brain Morphology 
Computed tomography (CT) studies with cohorts ranging from middle-aged to older adults report 
that chronic smoking is associated with an abnormal increase of global brain atrophy with advancing 
age [74-77]. These CT studies assessed whole brain volumes and did not report major anatomical 
subdivisions (e.g., frontal gray matter/white matter). An early MRI study with older adults examined 
global brain atrophy over a 5-year-interval and found higher pack years was related to increased 
ventricular volume in men and was associated with increased sulcal volume in women, after 
controlling for age and vascular risk factors [78]. More recent MRI studies have employed voxel-based 
morphological measures to assess the regional brain volumes and densities of the cortical gray matter Int. J. Environ. Res. Public Health 2010, 7          
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(GM). Smokers aged 39.5  10.3 years evidenced smaller volumes and lower tissue densities than did 
NSC in bilateral anterior frontal lobe regions; smokers also had smaller volume of the left dorsal 
cingulate cortex and lower GM density in the cerebellum. Anterior frontal cortex density was inversely 
related to pack-years [79]. Smokers aged 30.8  7.5 years demonstrated widespread GM volume and 
density reductions relative to NSC [80], particularly in the bilateral frontal lobes, cingulate gyrus and 
insula. Non-demented older adult smokers (75.0  3.4 years of age) exhibited reduced GM density in 
right precuneus, left posterior cingulate gyrus, right thalamus and bilateral precentral and middle 
frontal gyri compared to NSC [81].  
A MR-based study employed diffusion tensor imaging (DTI) and voxel based morphometry to 
assess microstructural integrity and morphology, respectively, of the corpus callosum in middle aged 
chronic smokers [82]. Contrary to expectations, smokers demonstrated higher fractional anisotropy 
(FA; higher FA values are considered to reflect greater microstructural integrity [83,84]) in the body 
and total corpus callosum than did NSC and no volume differences were observed between smokers 
and NSC in the corpus callosum. However, smokers with high levels of nicotine dependence (as 
reflected by scores on the Fagerstrom Test for Nicotine Dependence) had significantly lower FA 
values than both smokers with low levels of nicotine dependence and NSC. It is widely recognized 
from population-based studies, with middle-aged and older adults, that chronic smoking is associated 
with increased incidence of regional white matter (WM) signal hyperintensities on standard MR 
imaging (e.g., T2-weighted and FLAIR) [85-89]. WM hyperintensities are associated with decreased 
cerebral blood perfusion [90,91] and neurocognitive dysfunction [92,93]. Overall, the degree of 
smoking-related morphological changes observed appears to be contingent on the method and brain 
region under consideration.  
3.2. Brain Biochemistry  
A single volume proton (
1H) MR spectroscopy study with chronic smokers (36  11 years of age) 
observed lower N-acetylaspartate (NAA) concentration (surrogate marker of neuronal   
integrity [94,95]), in the left hippocampus relative to NSC. No group differences were observed for 
NAA in the anterior cingulate cortex (ACC), but choline-containing compound (Cho) levels (a marker 
of cell membrane turnover/synthesis [94,96]) were positively related to greater pack years in this 
region [97]. A single voxel 
1H spectroscopy study of glutamate levels in the left hippocampus and 
ACC observed no differences among current smokers (35  10 years of age), former smokers (42  10 
years of age) abstinent for 17  3 years and NSC (33  10 years of age) [98]. In the sole 
1H 
spectroscopy study investigating gamma aminobutyric acid levels (GABA; neuromodulator involved 
in the development and maintenance of substance use disorders [99-101]) in chronic smokers, cortical 
GABA concentrations were lower in female smokers (and modulated by menstrual cycle phase), but 
GABA levels were not different between male smokers and NSC [102].  
3.3. Brain Perfusion 
The vast majority of neuroimaging research on brain perfusion has investigated the effects of acute 
nicotine exposure, rather than the consequences of chronic cigarette smoking [18]. The few published 
reports specifically investigating chronic smokers indicate globally decreased brain perfusion relative Int. J. Environ. Res. Public Health 2010, 7          
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to NSC, as measured by CT 
133Xe inhalation [103,104] in older adults and single proton emission 
computed tomography (SPECT) [105] in adults aged 35.5  8.4 years; perfusion was inversely related 
to cigarette pack-years [105]. In a Xe-CT-based longitudinal study with community-dwelling older 
adults, decreases in global cerebral perfusion were independently associated with chronic smoking 
controlling for other vascular risk factors [106,107].  
Table 2. Computerized tomography and magnetic resonance neuroimaging studies of 
chronic smoking in adults (sorted by imaging modality, then age group). 
Authors 
[reference 
number] 
Smokers (n)  NSC 
(n) 
Age group/ 
mean age or 
(range) 
Neuroimaging 
modality 
Major findings (all findings are statistically 
significant unless otherwise indicated) 
Akiyama  
et al. (1997) 
[74] 
104 current and 
former smokers 
combined 
173 Young  to  older 
adults/ 
(22–89) 
CT 
(volumetric 
and cortical 
perfusion) 
A history of smoking (i.e., current or former 
smoking) was associated with lower global 
cerebral perfusion after control for hypertension, 
WM disease and age. Over approximately  
3 years, smokers showed greater decrease in 
global perfusion and greater global atrophy 
than NSC. 
Kubota  
et al. (1987) 
[76] 
159 current  
Non-smoking 
group contained 
177 never and 17 
“light” smokers 
NA Middle  aged 
and older 
adults/ 
(40–69) 
CT  Current smokers from 50 to 69 showed greater 
global atrophy than never/light smokers. 
Hayee et al. 
(2003) [75] 
219 current,  
Non-smoking 
group contained 
183 never smokers 
and 17 “light” 
smokers 
NA Middle  aged 
and older 
adults/ 
(40–70) 
CT  Current smokers between 50–70 years of age 
showed greater global atrophy than the  
non-smoking group. 
Brody et al. 
(2004) [79] 
19 current  17  Young to older 
adults/ 
(21–65) 
MRI  Smokers showed lower volumes and densities in 
the anterior frontal lobe GM, smaller volume of 
the left dorsal anterior cingulate gyrus, and 
lower GM density of the right cerebellum 
relative to NSC. Higher pack years was 
associated with lower anterior frontal GM. 
Gallinat 
et al. (2006) 
[80] 
22 current  23  Adults/ 
30.6 ± 7.7 
MRI  Smokers demonstrated smaller GM volumes and 
densities in frontal, temporal and occipital 
regions compared to NSC. Smokers also showed 
lower volume or density in the thalamus, 
cerebellum and other subcortical nuclei/regions. 
Higher pack years was related to lower frontal, 
temporal and cerebellar GM volume. 
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Table 2. Cont. 
Authors 
[reference 
number] 
Smokers  
(n) 
NSC 
(n) 
Age group/ 
mean age or 
(range) 
Neuroimaging 
modality 
Major findings (all findings are 
statistically significant unless otherwise 
indicated) 
Paul et al. (2008) 
[82] 
10 current  10  Middle aged 
adults/ 
38.5 ± 13.4 
MRI (diffusion 
tensor imaging)
Smokers showed higher fractional 
anisotropy (FA) in the body and whole 
corpus callosum than NSC. Smokers with 
low Fagerstrom Test for Nicotine 
Dependence scores (mean = 1.6) showed 
higher FA in the whole corpus callosum 
than smokers with high scores (mean = 5.6).
Longstreth et al. 
(2000) [78] 
3,301 total 
participants, 
numbers of NSC, 
and smokers not 
provided 
NA Older 
adults/>65 
MRI  Over 5 years, higher pack years in men was 
related to increased ventricular volume in 
men and associated with increased sulcal 
volume in women, after control for age and 
vascular risk factors. 
Almeida et al. 
(2008) [81] 
39 current  39  Older adults/ 
75.4 ± 3.3 
MRI  Smokers showed decreased GM densities in 
the posterior cingulate gyrus and precuneus 
bilaterally, right thalamus and right 
precentral gyrus. 
Epperson et al. 
(2005) [102] 
16 current  20  Adults/ 
34 ± 11 
MRS  Gamma-aminobutyric acid (GABA) levels n 
the occipital GM were not different between 
NSC and male smokers. Female smokers 
showed a significant reduction in GABA 
levels during the follicular phase of the 
menstrual cycle. GABA levels showed no 
changes after 48 hours of smoking cessation 
in both males and females. 
Gallinat et al. 
(2007) [97] 
13 current  13  Adults/ 
36.6 ± 10.1 
MRS  Smokers showed lower  
N-acetylaspartate levels than NSC in the left 
hippocampus. Higher pack years was related 
to higher choline-containing compounds in 
the anterior cingulate gyrus. 
Gallinat and 
Schubert (2007) 
[98]  
13 current 
9 Former 
13 Adults/ 
36.1 ± 9.8 
MRS  No significant group differences were 
observed in glutamate levels of the anterior 
cingulate cortex and left hippocampus. 
Note. CT: computed tomography; GM: Gray Matter; MRI: magnetic resonance imaging; MRS: magnetic 
resonance spectroscopy; NA: not available; NSC: non-smoking (never-smoker) control; WM: white matter. 
4. Neurocognitive and Neurobiological Effects of Acute Nicotine Exposure and Withdrawal  
When investigating chronic cigarette smoking-induced neurobiological and neurocognitive 
dysfunction alone, or in conjunction with AUD and other conditions, it is important to distinguish the 
effects of acute nicotine ingestion and withdrawal from the potential consequences of chronic exposure 
to the multitude of noxious compounds contained in cigarette smoke. While not the focus of this 
review, the general findings and implications are discussed regarding the effects of acute nicotine on Int. J. Environ. Res. Public Health 2010, 7          
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neurocognition and brain neurobiology, as measured with functional neuroimaging methods   
[i.e., functional MRI (fMRI), positron emission tomography (PET), single positron emission 
tomography (SPECT)]. 
4.1. Acute Nicotine Consumption, Nicotine Withdrawal and Neurocognition 
Acute nicotine administration has been found to transiently improve some areas of neurocognition 
in NSC and individuals with attention deficit hyperactivity disorder and schizophrenia-spectrum 
disorders, most substantially on measures of sustained attention and working memory [17,19,108]. 
Acute nicotine administration in nicotine deprived smokers is associated with improved cognitive task 
performance [109,110], whereas several studies report decrements in neurocognitive performance with 
nicotine administration to NSC (see [19] for review). A recent meta-analysis conducted by Heishman 
and colleagues [111] suggests that acute smoking or nicotine consumption, independent of withdrawal 
effects, is associated with enhanced function in the following domains of function: fine motor skills, 
alerting attention accuracy and response time, orienting attention reaction time, short-term episodic 
memory accuracy and working memory reaction time (but not accuracy). In non-clinical chronic smokers, 
the adverse effects of nicotine withdrawal are not typically apparent on neurocognitive function until 8–12 
hours after last nicotine dose [17,19,109,112]. Protracted duration from last cigarette smoked/nicotine 
administration to onset of withdrawal mediated disturbances in neurocognition is likely attributable to 
the maintenance of relatively high levels of plasma nicotine during waking hours due to repeated 
dosing of nicotine (via cigarettes) [113].  
4.2. Acute Nicotine Consumption, Nicotine Withdrawal and Neurobiological Function 
Several functional neuroimaging (PET, SPECT, fMRI) studies in active chronic smokers   
(see [21,22] for review) and a few functional MRI studies addressed the acute effects of nicotine 
administration on brain activity during task activation in healthy non-smokers [17,18,20]. The effects 
of acute cigarette smoking on functional neuroimaging modalities in non-smokers have not been 
investigated [18,20]. In chronic smokers, functional neuroimaging studies investigating responses to 
acute smoking or nicotine administration have shown are that acute nicotine administration is 
associated with decreased global cerebral blood flow, increased activity in the dorsolateral, inferior and 
mesial frontal and orbitofrontal regions, thalamus and visual processing regions (see [21,22]). In 
chronic smokers deprived of tobacco for more than 2 hours, acute cigarette smoking elicits different 
patterns of relative perfusion responses, with increases of the order of 6–8% in the anterior frontal and 
cingulate cortices as well as decreases in cerebellum and occipital lobes that were associated with 
plasma nicotine levels [18,114,115]. Some studies report a 7–10% decrease in global glucose 
utilization following acute nicotine administration in chronic smokers deprived of nicotine for 8 hours 
or more [116,117]. Depending on the nature of the task, results suggest acute nicotine administration in 
smokers and non-smokers is associated with increased regional blood flow/brain activity and improves 
task performance or decreases blood flow/oxygenation level-dependent activity and task performance 
[18,20]. As discussed by Sharma and Brody [22], the reported regionally specific findings may be 
influenced by whether or not activity was standardized to whole brain blood flow.  Int. J. Environ. Res. Public Health 2010, 7          
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Overall, the effects of acute nicotine administration on neurocognition and functional imaging 
measures appear to depend on duration of nicotine deprivation, the brain region studied, resting versus 
activation conditions, and the neurocognitive domain investigated [18].  
5. Potential Biological Mechanisms Contributing to Chronic Cigarette Smoking-Induced 
Neurocognitive and Neurobiological Dysfunction 
Nicotine is one of more than 4000 compounds composing the particulate and gas phases of cigarette 
smoke [5,8,118]. In addition to nicotine, scores of these compounds are bioactive and may affect tissue 
locally in the oral cavity, the upper and lower respiratory systems, and distally via the systemic 
circulation. The many potentially cytotoxic compounds in cigarette smoke (e.g., carbon monoxide, 
aldehydes, ketones, nitrosamines, dihydroxybenzenes) [119] may directly compromise neuronal and 
cellular membrane function of cerebral tissue. There are several potential mechanisms that may 
contribute independently, or in concert, to the neurobiological and neurocognitive abnormalities in 
chronic smokers. These mechanisms may operate in a direct and/or indirect manner. The following 
overview is based on in vivo and in vitro studies of animals and humans.  
5.1. Direct Mechanisms 
A significant number of potentially cytotoxic compounds (e.g., carbon monoxide, free radicals and 
their precursors, nitrosamines, phenolic compounds, and other polynuclear aromatic   
compounds [119]), are found in the gas and particulate phases of cigarette smoke, which may be directly 
cytotoxic, damage neuronal or glial cell organelles and promote oxidative damage ([120], Muscat, 2004 
#13479, [121,122]). For example, carbon monoxide (CO) levels are significantly higher in   
smokers [123], and this elevation is associated with decreased effective hemoglobin concentrations, 
diminished oxygen carrying capacity of erythrocytes [124], as well as a diminished efficiency of the 
mitochondrial respiratory chain [125]. Furthermore, cigarette smoke also contains high concentrations 
of free radical species (e.g., reactive nitrogen species; reactive oxygen species, ROS) known to 
promote oxidative damage or stress to cellular structures as well as to macromolecules including 
membrane lipids, proteins, carbohydrates and DNA [126]. The radical species in the particulate matter 
of cigarette smoke are long-lived (i.e., hours to months) compared to those in the gas phase [5], and 
can compromise organs other than the lungs [120,127]. In vivo chronic exposure of rat brain tissue to 
cigarette smoke significantly decreases membrane-bound ATPases, which alters ion homeostasis, and 
leads to increased Ca
2+ and Na
+ levels in the cytosol of various cell types [128], as well as increased 
Ca
2+ in mitochondria [122], which is associated with neuronal injury or death [129]. Increased 
mitochondrial Ca
2+ secondary to cigarette condensate exposure is associated with damage to the inner 
mitochondrial membrane (e.g., membrane swelling) and vacuolization of the matrix. Importantly, 
nicotine delivered independently of cigarette smoke does not appear to produce these adverse   
affects [122]. Nicotine administration in adolescent rats does, however, evoke cell injury and loss 
throughout the brain, with significant effects in the hippocampus of female rats but not   
males [130,131]. In general, the mechanisms underlying the observed nicotine-induced cell injury 
remain to be fully explicated.  
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5.2. Indirect Mechanisms  
In vivo chronic cigarette smoke exposure is also associated with decreased enzyme-based free 
radical scavenger (e.g., superoxide dismutase, catalase, glutathione reductase) and non-enzyme-based 
radical scavenger (e.g., glutathione and vitamins A, C and E) concentrations in rat brains [132,133]. 
This may render brain tissue more vulnerable to oxidative damage by radical species generated by 
cellular metabolism or other exogenous sources. The brain, in general, is exceedingly susceptible to 
oxidative damage because of high levels of unsaturated fatty acids in the composition of cell 
membranes and myelin. Additionally, chronic cigarette smoking is related to nocturnal hypoxia [7] as 
well as chronic obstructive pulmonary disease and other conditions that may impair lung function [8]. 
Decreased lung function is associated with poorer neurocognition and increased subcortical atrophy in 
older adults [134]. Chronic smoking increases the risk for atherosclerosis [9], as well as abnormalities 
in vascular endothelial morphology and function [135-138], which may alter cerebral perfusion. 
Additionally, nicotine administered through means other than cigarette smoke may alter or impair 
vasomotor reactivity of cerebral arterioles through upregulation of Ca
2+ channels and/or modulation of 
nitric oxide [136]. These processes may impact the functional integrity (e.g., vasomotor 
reactivity/responsivity) of the cerebrovasculature and may, at least partially, contribute to the 
decreased regional cerebral blood flow [114,115,139] and/or white matter disease [85,87-89,140,141] 
observed in chronic smoking. Both the neocortex and underlying WM are vulnerable to the effects of 
diffuse ischemia (see [142] and references therein). Correspondingly, it has been suggested that   
late-myelinating areas such as the frontal and temporal lobes may be particularly vulnerable to 
increased oxidative stress and cerebral hypoperfusion [143,144], both of which have been described in  
chronic smokers. 
Chronic smoking is also associated with central obesity (often reflected in increased body mass 
index; BMI) and/or insulin resistance [145], which, in turn, are reported to adversely affect brain 
neurobiology [146-149] and neurocognition [146,150].  
In summary, although nicotine is likely the principal bioactive agent that underlies the addictive 
properties of tobacco smoke [19,151-154], the reviewed literature suggests that the majority of adverse 
neurobiological and neurocognitive effects of chronic cigarette smoking are a function of the direct 
and indirect consequences of continual exposure of the cardiopulmonary system, cerebrovascular 
system and brain parenchyma to the combination of non-nicotine combustion products contained in 
cigarette smoke [13,14,155]. However, a significant amount of data regarding potential mechanisms 
contributing to the neurobiological and neurocognitive abnormalities observed in humans is derived 
from  in vitro and animal studies. Consequently, it is unclear if all potential mechanisms are 
generalizable to humans. 
6. Discussion 
The cumulative body of research reviewed suggests chronic cigarette smoking is associated with 
deficiencies in auditory-verbal learning and/or memory, general intellectual abilities, visual search 
speeds, processing speed, cognitive flexibility, working memory and executive functions, across a 
wide age range. With advancing age, chronic smoking is related to abnormal decline in reasoning, Int. J. Environ. Res. Public Health 2010, 7          
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memory and global cognitive function, and may increase the risk for both vascular dementia and 
Alzheimer’s Disease. However, several studies showed a weak or no association with smoking status 
and neurocognition. Chronic smoking is related to structural and biochemical abnormalities in multiple 
brain regions, particularly the anterior dorsolateral, mesial frontal cortex, limbic system and underlying 
WM. A dose-response relationship is suggested between cigarette smoking, neurocognition and 
neurobiological function. The reviewed literature suggests the adverse neurobiological and 
neurocognitive effects of chronic cigarette smoking in humans may be related to the direct and indirect 
consequences of continual exposure of the cardiopulmonary system, cerebrovascular system and/or 
brain parenchyma to the combustion products of cigarette smoke. However, the potential mechanisms 
contributing to the neurobiological abnormalities observed are derived from in vitro and animal 
studies. Consequently, it is unclear if these mechanisms are actually operational in humans. 
Furthermore, it is uncertain to what extent, if any, the reported neurocognitive and neurobiological 
abnormalities reported in smokers are influenced by premorbid or comorbid factors. Overall, the 
following methodological limitations are present in the reviewed literature:  
6.1. Confounding Variables 
Potentially confounding medical conditions (e.g., hypertension, diabetes, insulin-resistance, chronic 
obstructive pulmonary disease, atherosclerosis, neurodegenerative diseases) and comorbid alcohol 
use/misuse, substance use/misuse, and psychiatric conditions (particularly mood disorders) were   
not consistently screened or statistically accounted for in many studies. Several psychiatric   
disorders known to have adverse effects on brain neurobiology and neurocognition are highly   
prevalent in chronic smokers, including anxiety disorders [156], attention deficit/hyperactivity  
disorder [157,158], alcohol and substance use disorders [13,157,159], mood disorders [160,161], and  
schizophrenia-spectrum disorders [162,163]. Additionally, the potential influence of sex, exercise, diet, 
body mass index, exposure to secondary/environmental smoke, nicotine withdrawal and genetic 
predispositions [e.g., ApoE4 genotype, single nucleotide polymorphisms in nicotinic acetlycholinergic 
receptors (nAChr), brain derived neurotrophic factor (BDNF), dopamine receptor D2 (DRD2), 
catechol-O-methyl transferace (COMT)] were not considered. The aforementioned factors are likely 
mediators or moderators of brain neurobiology and neurocognition in controls and addictive   
disorders [146,147,149,164-181]. Finally, the potential effects of nicotine withdrawal on the primary 
measures of interest were not addressed in many studies. 
6.2. Limited Scope of Neurocognitive Assessment 
Overall, there are a limited number of studies in each age group that conducted a comprehensive 
assessment of neurocognition. Additionally, measures of executive function (e.g., Categories Test, 
Wisconsin Card Sorting Test, Wechsler Adult Intelligence Scale-III Matrix Reasoning) were seldom 
administered. In older adults, many of the population-based research used single screening measures of 
global cognitive function (e.g., MMSE), or employed a composite score based on a limited number of 
tests primarily used to assess the severity of cognitive dysfunction in neurodegenerative diseases. 
Additionally, only two studies [29,63] investigated the effects of chronic smoking on tasks specifically Int. J. Environ. Res. Public Health 2010, 7          
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assessing decision making, risk taking and impulsivity. Consequently, the full scope of the 
neurocognitive consequences associated with chronic smoking remains unclear.  
6.3. Limited Number of Neurocognitive Studies in Young Adults 
The vast majority of studies investigating the neurocognitive consequences of chronic cigarette 
smoking have been conducted in middle aged and older adults. There is a particular shortage of studies 
in the 30–40 years of age range. 
6.4. Limited Number of Neuroimaging Studies  
Previous neuroimaging research assessing the chronic effects of cigarette smoking has been 
primarily restricted to a few CT and MR-based studies of brain morphology, metabolites or blood 
flow, which primarily targeted neocortical and subcortical GM. Only one study investigated WM 
integrity via DTI. Prospective multimodal neuroimaging studies thoroughly examining WM 
morphology, biochemistry and perfusion of regional cerebral WM have not been conducted. 
Assessment of the cerebral WM is vital to better understand the extent of potential neurobiological 
dysfunction associated with chronic cigarette smoking.  
6.5. Limited Longitudinal Research 
The vast majority of studies assessing the neurocognitive and neurobiological consequences   
of chronic smoking are cross-sectional in design. The few longitudinal neurocognitive and 
neuroimaging-based studies were conducted with older adult cohorts.  
6.6. Absence of MR-based Studies Examining Relationships between Brain Neurobiology and 
Neurocognition 
No study has concurrently combined MR-based neurobiological measures with comprehensive 
neurocognitive assessment in order to study the correspondence between brain function and 
neurocognition. Studies relating MR-based brain volumetric and metabolite measures to 
neurocognition in substance dependent populations have observed different patterns/relationships for 
smokers and non-smokers [182,183] suggesting a differential use of compensatory functions in 
smokers and non-smokers to accomplish the same task.  
7. Conclusions 
Increasing evidence suggests that chronic smoking in community-dwelling participants is associated 
with diminished function of multiple neurocognitive abilities and neurobiological abnormalities. The 
cumulative pattern of neurocognitive findings suggests dysfunction prominently in neurocircuitry 
implicated in decision making, impulse control, judgment, planning and reasoning skills, and in the 
initiation and maintenance of substance use disorders [184-187]. Specifically, the pattern of the 
neurocognitive and neurobiological findings in chronic smokers points to abnormalities in the brain 
reward system [186-188]. Major components of the brain reward system include (but are not limited 
to) the dorsolateral prefrontal cortex, orbitofrontal cortex, insula, anterior cingulate cortex, Int. J. Environ. Res. Public Health 2010, 7          
 
3778
hippocampus, amygdala, nucleus accumbens, ventral tegmental area and other nuclei in the basal 
forebrain and ventral pallidum [186,189-191]. Plastic changes in the brain reward system are 
implicated in the development and maintenance of all substance use disorders, including nicotine 
dependence, and other maladaptive behaviors [186-188,192-194]. However, the actual mechanisms 
promoting the neurocognitive and neurobiological abnormalities reported in chronic smokers are 
unclear and premorbid variables(e.g., genetic vulnerabilities) must also be considered as potential 
contributing factor. More specifically, the neurobiological and neurocognitive abnormalities reported 
in the reviewed studies may represent premorbid risk factors for the development and maintenance of 
nicotine dependence and/or premorbid vulnerabilities that were compounded by the effects of chronic 
smoking. Additionally, as many studies of the neurocognitive consequences of chronic smoking were 
conducted with older adults, the reported findings may be influenced by a survivor effect [43].  
To assist in clarifying the factors contributing to the reported neurocognitive and neurobiological 
dysfunction, studies are needed that: 
1.  Concurrently assess cohorts of males and females ranging from young to older adults.  
2.  Employ prospective multi-modality neuroimaging studies (i.e., combining brain morphology, 
biochemistry, perfusion, and metabolism in the same cohort), with particular attention to the 
brain reward system.  
3.  Employ comprehensive neurocognitive testing including behavioral measures of impulsivity, 
decision-making and risk taking [24,195,196]. 
4.  Consider genetic factors (e.g., ApoE genotype, single nucleotide polymorphisms in BDNF, 
nAChr, DRD2, COMT, glutamate receptors) implicated in the development and maintenance 
of substance use disorders (see [197-200]). Such an approach would better delineate the extent 
and magnitude of the neurobiological and neurocognitive consequences of chronic cigarette 
smoking, the roles of common genetic variations in vulnerability to nicotine dependence and 
their inter-relationships.  
5.  Employ prospective serial longitudinal studies to assess changes in neurobiology and 
neurocognition over extended periods in chronic smokers (e.g., >5 years). Additionally, it is 
vital to conduct prospective pre-and-post neuroimaging and neurocognitive studies with 
individuals engaging in smoking cessation programs to determine if smoking-related 
neurobiological and neurocognitive abnormalities recover with smoking cessation, and to 
assess the effect of pharmacologic interventions (e.g., nicotine replacement, varenicline) on 
neurobiological and neurocognitive changes. Such longitudinal studies will assist in 
determining if the neurocognitive and/or neurobiological abnormalities observed in   
cross-sectional studies are related to premorbid factors.  
In conclusion, chronic cigarette smoking appears to be associated with demonstrable abnormalities 
in brain neurobiology and neurocognition in cross-sectional research across the lifespan, and is related 
to abnormal rates of brain volume loss in the elderly. However, the mechanisms promoting these 
abnormalities have yet to be explicated in humans. To better understand the factors associated with the 
reported neurocognitive and neurobiological abnormalities, longitudinal research combining 
comprehensive neurocognitive assessment with neuroimaging of brain metabolites, microstructure, 
macroscopic morphology, brain function and genetic vulnerabilities are necessary. Such longitudinal Int. J. Environ. Res. Public Health 2010, 7          
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studies are required to inform the development of more effective pharmacological and behavioral 
interventions to reduce the ever-increasing worldwide mortality and morbidity associated with the 
modifiable health risk that is chronic cigarette smoking.  
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